Parameter	%
Proportion of patients with grade 3 and above CRS	14
Proportion of patients treated with tocilizumab	23
Proportion of patients treated with IVIG	47

Note: Grupp et al. (2019)¹⁴ analyzed real-world data from patients with relapsed/refractory B-cell pediatric ALL who received tisagenlecleucel from 45 centers in the United States through the Center for International Blood and Marrow Transplant Research Cellular Therapy registry (data cutoff September 2019). Safety outcomes were available from 154 patients, who had at least 3 months of follow-up after infusion. Median follow-up time was 6 months (range: < 1-14 months) among survivors. The American Society for Transplantation and Cellular Therapy consensus criteria were used to assess and grade CRS.

ALL = acute lymphoblastic leukemia; CRS = cytokine release syndrome; IVIG=intravenous immunoglobulin.